Campanilho-Marques R, Deakin CT, Simou S, et al. - This study was intended to present the usage of infliximab and adalimumab therapy in juvenile dermatomyositis as an adjunctive treatment. Researchers recruited a total of 60 children to the UK Juvenile dermatomyositis Cohort and Biomarker Study that had received at least 3 months of anti-TNF treatment (infliximab or adalimumab). They noted childhood Myositis Assessment Scale, Manual Muscle Testing and physician’s global assessment. The modified skin disease activity score was applied to evaluate skin disease. Friedman’s test was applied to examine data for repeated measures analysis of variance. This study's findings reveal reductions in muscle and skin disease, involving calcinosis, following treatment with infliximab and adalimumab.